Researchers from the universities of Basel and Zurich have used a historical specimen from UZH's Medical Collection to decode ...

Pepper’s last contribution to science was in May 2021, when he brought home a common cotton mouse carrying a type of ...

Influenza virus articles from across Nature Portfolio Influenza virus is an infectious agent belonging to the virus family Orthomyxoviridae that causes a respiratory tract infection (influenza or ...

Influenza Influenza is an RNA virus in the Orthomyxoviridae family and its most common subtypes are A and B. Infection typically leads to more severe symptoms than the common cold.

Influenza viruses belong to the Orthomyxoviridae family and are divided into four main types: A, B, C, and D. Among these, Flu A and Flu B are the primary culprits responsible for seasonal flu ...

Two types of influenza viruses are responsible for seasonal flu outbreaks: Influenza A and B. Influenza A accounts for around 75 percent of all cases and tends to cause more severe illness in adults.

As the Centers for Disease Control and Prevention (CDC) explains, bird flu is a disease caused by the influenza A virus. At the same time, recent CDC data shows that seasonal influenza A is rising ...

Influenza viruses are becoming increasingly resilient to medicines. For this reason, new active ingredients are needed. Important findings in this regard have been provided: for the virus to ...

Novel, needle-free, live-attenuated influenza vaccines with broad protection against human and avian virus subtypes Date: May 9, 2025 Source: The University of Hong Kong Summary: A research team ...

Influenza A is believed to be the most severe type of flu virus for humans, although this is the subject of debate, as there is some evidence to suggest that influenza B might be equally as dangerous.

As the seasonal flu picks up, there are even more opportunities for the bird flu to acquire mutations as the different influenza viruses mix.

EV25, an antiviral therapeutic developed by biotech company Eradivir, has shown in preclinical studies to reduce lung viral loads of advanced-stage influenza quicker than current therapies.